This Week in Gene & Cell Therapy: Gene Therapy Milestones, Strategic Shifts, and Breakthroughs in Oncology and Cardiology 🧬
From AviadoBio’s latest FTD-GRN trial progress to Sangamo’s regulatory momentum in Fabry disease, this week brings groundbreaking advances across gene therapy, oncology, regenerative medicine, and cardiovascular research!
💡 Top Highlights This Week:
🧠 AviadoBio completes its second AVB-101 cohort with no major safety concerns, continuing recruitment across the U.S. and Europe
🧪 March Biosciences receives a 💲200K G-Rex grant to scale up MB-105, a CAR-T therapy for CD5+ T-cell cancers
🧊 BioIVT launches VivoSTART – GMP cryopreserved leukopaks designed to streamline CGT manufacturing and inter-lab standardization
🔁 Vertex exits AAV-based gene therapy research, shifting focus to programs like Casgevy and zimislecel
👁️ Odylia Therapeutics announces an AAV-based gene therapy targeting NPHP1-related retinal dystrophy, aiming for a 2027 IND
🧠 Genprex licenses REQORSA for glioblastoma, adding to its expanding oncology gene therapy pipeline
🧬 Genezen & Optieum partner on OPTF01, a CAR-T therapy for glioblastoma leveraging FAPα targeting and the proprietary Eumbody System
❤️ Capricor completes FDA mid-cycle review for Deramiocel, a first-in-class cell therapy for DMD-related cardiomyopathy
⚙️ Sangamo reaches major regulatory milestones for ST-920 in Fabry disease, with pivotal data expected in mid-2025 and BLA submission planned for early 2026
🌍 Whether you’re a biotech professional, clinician, or investor, these updates are essential for staying ahead in gene and cell therapy innovation.
📢 Stay Ahead in Gene & Cell Therapy Research!
✅ Like, share, and subscribe for weekly updates
#GeneTherapy #CellTherapy #CAR_T #Glioblastoma #FabryDisease #DMD #BiotechNews #ClinicalTrials #OncologyResearch #HealthcareInnovation #LucidQuest